Industry Analysis & Industry Trends
With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience a boost in demand. Rising production of branded follow-on biologic drugs will be important in offsetting the effects of widespread patent expirations, though a major increase in taxes and discounts to fill the Medicare coverage gap threatens profit in the industry... purchase to read more
Industry Report - Industry Locations Chapter
Brand-name pharmaceutical manufacturers have contended with fewer clinical trials being conducted in the United States over the past five years. While India, China and Japan are exhibiting robust growth in their number of clinical trials, the United States still accounts for the largest share of clinical trials. According to the National Institutes of Health, 47.0% of total clinical trials were conducted in the United States in 2011 (latest data available).
Location decisions by the industry for clinical trials appear to align more closely with pharmaceutical sales than with available patient populations. Strong pharmaceutical sales in the United States has caused many manufacturers to invest in R&D and drug testing... purchase to read more